Adding bevacizumab to platinum-based chemotherapy may improve survival among women with recurrent ovarian cancer, according to a study published in Lancet Oncology.1
Bevacizumab is emerging as an effective strategy as a first-line or maintenance therapy for recurrent ovarian … Read more
Avastin (bevacizumab) gained an expanded FDA approval to treat patients with platinum-sensitive recurrent ovarian cancer as a part of a combination regimen with chemotherapy followed by continued use of the angiogenesis inhibitor, according to the drug developer, Genentech.
The approval … Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
